Medistem makes Alan Lewis CEO
This article was originally published in Clinica
Adult stem cell company Medistem has appointed Dr Alan Lewis CEO and a member of the board of directors. Dr Lewis has been a member of Medistem's scientific advisory board since January 2012. He has previously served as CEO of Signal Therapeutics, Novocell and the Juvenile Diabetes Research Foundation, and is currently a board member of BioMarin. He replaces Dr Thomas Ichim, who has served as CEO since 2008 and has now been appointed Medistem's president and chief scientific officer.